A bisalp, short for bilateral salpingectomy, is a surgical procedure that removes both fallopian tubes entirely. Originally performed to treat ectopic pregnancies or infected tubes, it has become the preferred method of permanent contraception for many gynecologists because it also lowers the risk of ovarian cancer. The shift away from traditional tubal ligation toward bisalp has accelerated over the past decade as research has clarified where ovarian cancer actually begins, and the procedure is now endorsed by major medical organizations as a sterilization option worth discussing with anyone seeking permanent birth control.
How the Procedure Works
A bisalp is typically performed laparoscopically, meaning the surgeon works through two or three small incisions in the abdomen rather than one large cut. A camera and thin instruments are inserted through the incisions, and the surgeon identifies each fallopian tube, seals off its blood supply, and removes it completely. The ovaries and uterus stay in place. The whole operation usually takes about 30 to 45 minutes under general anesthesia, though times vary depending on whether it is done as a standalone procedure or added onto another surgery like a cesarean delivery or hysterectomy.
This is different from a tubal ligation, where the tubes are clipped, banded, burned, or cut but left mostly in place. A bisalp takes the tubes out altogether. That distinction matters both for contraceptive reliability and for cancer prevention, which is why the procedure has gained so much ground.
What Recovery Looks Like
Most people who have a laparoscopic bisalp go home the same day. The small incisions cause less tissue disruption than open surgery, so recovery tends to be straightforward. Expect some abdominal soreness, bloating from the gas used to inflate the abdomen during surgery, and mild shoulder pain from that same gas irritating the diaphragm. These symptoms usually peak in the first day or two and fade within a week.
Most people return to desk work and light activity within a week and resume exercise and heavier physical tasks within two to three weeks, though your surgeon will give you a specific timeline. Lifting restrictions are common for the first couple of weeks. Periods continue as usual after a bisalp because the ovaries and uterus are untouched. The procedure does not trigger menopause or change your cycle.
Why Ovarian Cancer Prevention Matters Here
The cancer-prevention angle is the single biggest reason bisalps have overtaken tubal ligation. For decades, researchers assumed ovarian cancer started in the ovaries themselves. Over the past two decades, molecular studies have overturned that assumption. Most high-grade serous ovarian cancers, the deadliest subtype, appear to originate in the cells lining the far end of the fallopian tube, called the fimbria. Precancerous changes in those cells can transform into malignant growths that then spread to the neighboring ovary.
These precursor lesions have been found even in people with no genetic predisposition to ovarian cancer, which means the cancer-prevention benefit of removing the tubes is not limited to those carrying BRCA mutations or other high-risk gene variants.
How Much Does a Bisalp Lower Ovarian Cancer Risk
Traditional tubal ligation already reduces ovarian cancer risk to some degree, likely by disrupting the pathway between the tube and the ovary. Studies have estimated that tubal ligation cuts the risk of any ovarian cancer by roughly 13 to 41 percent. Bilateral salpingectomy does substantially better: estimates range from about 42 to 78 percent risk reduction.
A large population-based study of nearly 197,000 people compared those who had a bisalp with those who had other gynecologic surgeries. In the bisalp group, the risk of any ovarian carcinoma dropped by about 40 percent, and the risk of serous ovarian carcinoma specifically, the subtype most clearly linked to fallopian tube origins, dropped by roughly half.
It is worth being clear-eyed about what these numbers mean in practice. Ovarian cancer is not common in the general population, so even a large relative risk reduction translates to a modest absolute difference for any individual person. But ovarian cancer is disproportionately lethal because it is usually caught late, which makes even modest prevention gains meaningful. One cost-effectiveness analysis estimated that in 10,000 people choosing sterilization at the time of cesarean delivery, switching from tubal ligation to bisalp would prevent about 17 ovarian cancer diagnoses and 13 ovarian cancer deaths.
Effects on Hormones, Ovarian Reserve, and Menopause
A common worry is that removing the fallopian tubes will somehow damage the ovaries or trigger early menopause. The tubes sit close to the ovaries and share some blood supply, so the concern is not unreasonable. But the weight of evidence is reassuring.
Multiple studies have measured anti-Müllerian hormone (AMH), a marker of ovarian reserve, before and after bisalp. A meta-analysis found no statistically significant change in AMH levels after the procedure, and subgroup analyses looking at patient age and whether one or both tubes were removed all came to the same conclusion.
A separate study tracked hormone levels at three months and nine months after surgery in people who had a bisalp added to a hysterectomy compared with those who had a hysterectomy alone. There were no significant differences in AMH, estrogen, FSH, LH, or follicle counts between the two groups at either time point.
On the question of whether bisalp triggers earlier menopause, a large cohort study from British Columbia followed people for years after the procedure and found no increase in physician visits related to menopause and no earlier initiation of hormone replacement therapy compared with controls. That held true across all age groups and even in people followed for at least five years.
One Swedish study did find a slightly higher rate of menopausal symptoms one year after hysterectomy with bisalp compared to hysterectomy alone. But that study looked specifically at the hysterectomy-plus-bisalp combination, and the finding has not been consistently replicated. The overall picture is that bisalp does not meaningfully hasten menopause, though researchers acknowledge that the theoretical concern about long-term effects on ovarian blood supply warrants continued follow-up.
How Effective Is It as Birth Control
A bisalp is one of the most effective forms of contraception available. Because the entire tube is removed rather than merely blocked, there is essentially no pathway for an egg and sperm to meet. Traditional tubal ligation, by contrast, has a small but real failure rate: clips can slip, burned tissue can heal, and tubal channels can recanalize over time.
One systematic review comparing bisalp to tubal ligation found a lower pregnancy rate with bisalp, though the difference just missed conventional statistical significance.
Pregnancies after bisalp are extraordinarily rare. A 2022 systematic review identified only four reported cases of spontaneous intrauterine pregnancy after a complete bilateral salpingectomy. Ectopic pregnancies are also possible in unusual locations. One case report described an ectopic pregnancy implanting in the round ligament after bisalp, a reminder that even when the tubes are gone, an embryo can occasionally find an abnormal site to implant. These cases are medical curiosities more than realistic risks, but they are worth knowing about so that anyone experiencing unexpected pelvic pain after a bisalp takes it seriously.
Risks and Complications
No surgery is risk-free, and a bisalp is no exception. A population-based cohort study of over 7,100 bisalp procedures found an overall complication rate of about 2.8 percent. Most of those were minor complications, occurring in roughly 1.9 percent of cases, while major complications occurred in about 0.7 percent.
How does that compare with tubal ligation? The answer depends on which study you look at. A systematic review and meta-analysis found few differences between bisalp and tubal ligation in most clinical outcomes: blood loss, length of hospital stay, pre- and postoperative complications, and wound infections were all comparable. However, a separate large database analysis found that bisalp was associated with higher rates of longer operation time, longer hospital stay, readmission, and unplanned reoperation compared to tubal ligation. That study also found higher rates of surgical site infection and sepsis in the bisalp group, though these events were still uncommon in absolute terms.
The discrepancy between these findings likely reflects differences in study design and patient populations. In practice, professional guidelines from organizations like the American College of Obstetricians and Gynecologists have concluded that bisalp performed at the time of hysterectomy or as a sterilization method does not meaningfully increase the risk of complications such as blood transfusions, readmissions, infections, or fever compared to the alternatives.
IVF After a Bisalp
Because a bisalp is permanent, a natural question is whether pregnancy is still possible through in vitro fertilization. The answer is yes. IVF bypasses the fallopian tubes entirely: eggs are retrieved directly from the ovaries, fertilized in a lab, and transferred into the uterus. Having no tubes does not change any of those steps.
In fact, for people with certain types of tubal disease, having the tubes removed before IVF actually improves outcomes. One study of patients with severe tubal factor infertility found that those who had a prior salpingectomy had a higher embryo implantation rate and a higher ongoing pregnancy rate per IVF transfer compared with those whose damaged tubes were left in place. Another study found that bilateral salpingectomy in people with fluid-filled tubes (hydrosalpinges) restored delivery and implantation rates to normal levels, matching those of IVF patients without tubal disease. The beneficial effect held even for people who had multiple prior IVF failures before surgery.
So while a bisalp permanently closes the door on conceiving without medical assistance, it does not impair IVF success, and it can actually improve it if damaged tubes were contributing to fertility problems.
Cost-Effectiveness
On a per-patient basis, a bisalp costs slightly more than a tubal ligation. One analysis of sterilization performed at the time of cesarean delivery found the cost of the bisalp strategy was about $3,651 compared with $3,588 for tubal ligation, a difference of roughly $63. But that small added cost came with slightly better outcomes in terms of quality-adjusted life-years, largely because of the cancer prevention benefit and lower unintended pregnancy rate. The analysis concluded that bisalp was cost-effective, with the incremental cost per quality-adjusted life-year falling well below standard thresholds that health economists consider a good value.
A second cost-effectiveness analysis reached a similar conclusion, estimating that in 10,000 people choosing sterilization with cesarean, bisalp would result in 17 fewer ovarian cancer diagnoses, 13 fewer ovarian cancer deaths, and 25 fewer unintended pregnancies compared with tubal ligation, at an additional cost of about $4.7 million across the entire group. The per-person cost increase is modest; the population-level benefits are concrete.
Regret Rates and Who Is Most Affected
Any permanent contraceptive procedure carries the possibility of regret, and bisalps are no different. A study evaluating regret among people who had either a tubal ligation or bilateral salpingectomy for contraception found that about 16 percent of respondents reported some degree of regret. The factors most strongly linked to regret were younger age at the time of surgery, a change in relationship status afterward, and having the procedure performed during a pregnancy (for example, during a cesarean delivery).
Those findings are consistent with decades of research on sterilization regret more broadly. They do not mean people under 30 should not have a bisalp, but they do suggest that younger individuals and those whose life circumstances are more likely to shift should be especially deliberate during the decision-making process.
Getting Access Can Be Harder Than It Should Be
For many people, the biggest obstacle to a bisalp is not the surgery itself but finding a provider who will agree to perform it. A national survey of obstetrician-gynecologists in the United States found that while virtually all (98 percent) would help a patient obtain sterilization, a significant proportion would actively try to dissuade certain patients based on their age, number of children, or partner’s opinion. Nearly half would discourage someone who had only one child, and about a third would discourage even someone with three children. Strikingly, a majority of physicians said they would discourage a 26-year-old whose husband disagreed with the decision, while only about a third would discourage the same patient if her husband agreed.
This gatekeeping disproportionately affects younger people and those without partners who endorse the decision. Some patients report being told to “wait until you’re older” or “come back after you’ve had children,” advice that reflects physician anxiety about regret rather than evidence that these patients are making poor decisions. The pattern is well-documented enough that online communities have sprung up specifically to share the names of providers willing to perform sterilization without excessive resistance.
Insurance coverage varies. In the United States, the Affordable Care Act requires most private insurance plans to cover FDA-approved contraceptive methods for women without cost-sharing, and many insurers now classify bisalp under that mandate. However, coverage details can differ depending on the plan, and people with certain employer-sponsored or religious-exemption plans may face out-of-pocket costs. Checking with your insurer before scheduling is worth the phone call.
When a Bisalp Is Done Alongside Other Surgery
A bisalp does not have to be a standalone operation. It is increasingly performed “opportunistically,” meaning it is added to another planned surgery such as a hysterectomy or cesarean delivery. When a surgeon is already operating in the pelvis, removing the tubes adds a relatively small amount of time and does not appear to increase the rate of surgical complications.
The evidence supporting this comes from multiple directions. The ACOG committee opinion on opportunistic salpingectomy states that adding the procedure to a hysterectomy or performing it instead of tubal ligation is safe, with no increase in blood transfusions, readmissions, complications, infections, or fever. Studies of bisalp at the time of cesarean delivery have reached broadly similar conclusions. The additional operating time is generally modest, and the cancer-prevention benefit starts immediately because the tissue where precancerous changes develop is now gone.
For people already scheduled for pelvic surgery who have completed childbearing, asking about opportunistic salpingectomy is a straightforward conversation to have with your surgeon. Even for those not specifically seeking sterilization, the cancer-prevention rationale may be worth discussing if the ovaries are being preserved. Not everyone will want the procedure, and informed consent should always include a clear explanation that while bisalp reduces ovarian cancer risk, it does not eliminate it entirely.